Horizon Therapeutics (HZNP) Tops Q4 EPS by 6c

Horizon Therapeutics (NASDAQ: HZNP) reported Q4 EPS of $1.41, $0.06 better than the analyst estimate of $1.35. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $995.87 million.

GUIDANCE:

Horizon Therapeutics sees FY2022 revenue of $3.9-4 billion, versus the consensus of $3.91 billion.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15